$ALZN SEC Filings

Filed On	Filing
09 Oct 2026	RW
29 Sep 2026	8-K: Regulation FD Disclosure DEPARTMENT OF RADIOLOGY Pharmacokinetics imaging of lithium at 7T – results from a phase 1/2A clinical trial with a novel organic lithium salt Massachusetts General Hospital HARVARD Medical School Ovidiu C. Andronesi , Katherine N. Maina...
10 Sep 2026	10-Q
31 Aug 2026	Form 4: Ault Milton C Iii, Director Sold 2,000 shares ($3.12K)
31 Aug 2026	Form 4/A: Ault Milton C Iii, Director Bought 110,388 shares ($111K)
31 Aug 2026	Form 4/A: Ault Milton C Iii, Director Bought 110,388 shares ($111K)
28 Aug 2026	PRE 14A
21 Aug 2026	S-1
20 Aug 2026	Form 4/A: Hyperscale Data, Inc., Director and 2 others Granted 7,500 Series D Convertible Preferred Stock ($7.5M)
20 Aug 2026	Form 3/A: Hyperscale Data, Inc., Director and 2 others
04 Aug 2026	Form 4: Hyperscale Data, Inc., Director Granted 7,500 Series D Convertible Preferred Stock ($7.5M)
04 Aug 2026	Form 3: Hyperscale Data, Inc., Director
04 Aug 2026	Form 4: Ault Milton C Iii, Director Granted 7,500 Series D Convertible Preferred Stock ($7.5M)
04 Aug 2026	Form 5: Nisser Henry Carl, Director Granted 60,000 Stock Options (Right to Buy)
04 Aug 2026	Form 5: Ault Milton C Iii, Director Granted 100,000 Stock Options (Right to Buy)
04 Aug 2026	Form 5: Horne William B., Director Granted 60,000 Stock Options (Right to Buy)
04 Aug 2026	Form 5: Oram Jeffrey, Director Granted 60,000 Stock Options (Right to Buy)
04 Aug 2026	Form 5: Gustafson Mark, Director Granted 60,000 Stock Options (Right to Buy)
04 Aug 2026	Form 5: Jackman Stephan, Director Granted 450,000 Stock Options (Right to Buy)
04 Aug 2026	Form 5: Katzoff David J, Chief Financial Officer Granted 300,000 Stock Options (Right to Buy)

Comments